Minmin Chen

No ORCID on file · 5 papers in corpus · active 2023-2025

Study types

  • article 5

Condition tags

  • adenomyosis 5
  • dysmenorrhea 1
article 2025
Journal of ethnopharmacology ·doi:10.1016/j.jep.2025.119570
article 2024
Free radical biology & medicine ·doi:10.1016/j.freeradbiomed.2024.03.012

In various hyperproliferative disorders, damaged mitochondria can release mitochondrial DNA (mtDNA) into the cytoplasm, activating the cGAS-STING signaling pathway and subsequent immune imbalances. Our previous research has demonstrated tha…

article 2023
Frontiers in cellular and infection microbiology ·doi:10.3389/fcimb.2023.1075387

Background Adenomyosis (AM) is a benign uterine disease characterized pathologically by the invasion of endometrial tissue into the myometrium. The pathogenesis of AM is still far from clear. Although the gut microbiome and metabolomics are…

article 2023
Frontiers in pharmacology ·doi:10.3389/fphar.2023.1089004

Introduction: Dahuang-Taoren (DT) is a classic combination of botanical drugs applied to treat pain-related diseases in ancient China. Today, DT is frequently applied for dysmenorrhea of adenomyosis (AM) in the clinic. Growing evidence indi…

article 2023
PeerJ ·doi:10.7717/peerj.16497

Abstract Background: Recent studies indicate that endometrial hypoxia plays a critical role in adenomyosis (AM) development. Mitochondria are extremely sensitive to hypoxic damage, which can result in both morphological and functional impai…